Telix and Merck pan-cancer clinical collaboration
Filed with ASX · · 2 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallMelbourne (Australia) – 18 August 2021. Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that it has entered into a pan-cancer clinical collaboration with Merck KGaA, Darmstadt, Germany (‘Merck’), to conduct combination studies with one of Merck’s investigational proprietary DNA Damage Response Inhibitor (DDRi) molecules in combination with 177 177 each of Telix’s T
Telix Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Telix Pharmaceuticals
- TLX66 in Phase II Academic Study of Pediatric Leukemia
- Telix Seneffe Production Facility - Progress Update
- App 4C and Activities Report for June 2021 Quarter
- ZIRCON Phase 3 Renal Cancer Imaging Study - Progress Update
- TLX101 for Glioblastoma Therapy - Clinical Trial Update
Later from Telix Pharmaceuticals
- App 4D and Report for Half-Year Ended 30 June 2021
- Results Presentation and Shareholder Update 1H 2021
- Telix and Radius sign Distribution Agreement for Italy
- FDA Approves Phase II Kidney Cancer Therapy Study
- FDA Extends New Drug Application Review Period for Illuccix
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals